- **Geoff McDonough, MD** will step down as Chief Executive Officer and President of Generation Bio Co. and become **Chair of the Board of Directors**, effective **October 31, 2025**.  **[1733294_0001104659-25-101535_gbio-20251021xex99d1.htm:0]** **[1733294_0001104659-25-101535_gbio-20251021x8k.htm:1]** 
- **Yalonda Howze, JD**, the current Chief Legal Officer, has been appointed **Interim Chief Executive Officer and President**, effective **October 31, 2025**.  **[1733294_0001104659-25-101535_gbio-20251021xex99d1.htm:0]** **[1733294_0001104659-25-101535_gbio-20251021x8k.htm:1]** 
- Dr. McDonough will receive approximately **$700,000** in cash severance, a prorated bonus of approximately **$300,000**, and acceleration of vesting for **25%** of his outstanding unvested equity awards.  **[1733294_0001104659-25-101535_gbio-20251021x8k.htm:1]**  He will also provide advisory services as a consultant until **October 31, 2026**, at **$500 per hour**, with continued equity vesting.  **[1733294_0001104659-25-101535_gbio-20251021x8k.htm:1]** 
- As Interim CEO, Ms. Howze's annual base salary will be **$575,000**, with an annual target bonus of **50%** of her base salary, prorated for 2025.  **[1733294_0001104659-25-101535_gbio-20251021x8k.htm:2]** 
- Antoinette Paone (Chief Operating Officer) and Phillip Samayoa (Chief Scientific Officer) will also terminate their employment effective **October 31, 2025**, and will enter into consulting agreements until **October 31, 2026**, with hourly fees of **$360** and **$400**, respectively, and continued equity vesting.  **[1733294_0001104659-25-101535_gbio-20251021x8k.htm:2]**

Generation Bio (GBIO)